The site is undergoing maintenance on
If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
See More
BD Horizon™ BV786 Mouse Anti-Human CD70
Clone Ki-24 (RUO)
Flow cytometric analysis of CD70 expression on human U266 cells. Cells from the human U266 (Myeloma, ATCC TIB-196) cell line were stained with either BD Horizon™ BV786 mIgG3, κ Isotype Control (Cat. No. 565361; dashed line histogram) or BD Horizon BV786 Mouse Anti-Human CD70 antibody (Cat. No. 565338, solid line histogram). The fluorescence histogram showing CD70 expression (or Ig Isotype control staining) was derived from gated events with the forward and side light-scatter characteristics of viable U266 cells. Flow cytometric analysis was performed using a BD™ LSR II Flow Cytometer System.
Flow cytometric analysis of CD70 expression on human U266 cells. Cells from the human U266 (Myeloma, ATCC TIB-196) cell line were stained with either BD Horizon™ BV786 mIgG3, κ Isotype Control (Cat. No. 565361; dashed line histogram) or BD Horizon BV786 Mouse Anti-Human CD70 antibody (Cat. No. 565338, solid line histogram). The fluorescence histogram showing CD70 expression (or Ig Isotype control staining) was derived from gated events with the forward and side light-scatter characteristics of viable U266 cells. Flow cytometric analysis was performed using a BD™ LSR II Flow Cytometer System.
Product Details
BD Horizon™
CDw70; CD27 ligand; CD27-L; CD27L; CD27LG; Ki-24 antigen; TNFSF7
Human (QC Testing)
Mouse IgG3, κ
Human L428 Cell Line
Flow cytometry (Routinely Tested)
5 µl
III 166; IV A109
AB_2739192
Aqueous buffered solution containing BSA and ≤0.09% sodium azide.
RUO
Preparation And Storage
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon™ BV786 under optimum conditions, and unconjugated antibody and free BD Horizon™ BV786 were removed.
Recommended Assay Procedures
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD Optibuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Product Notices
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Cy is a trademark of GE Healthcare.
- BD Horizon Brilliant Violet 786 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
Companion Products
Brilliant Stain Buffer RUO
Size
100 Tests
Cat No.
563794
Stain Buffer (FBS) RUO
Size
500 ML
Cat No.
554656
Stain Buffer (BSA) RUO
Size
500 ML
Cat No.
554657
565338 Rev. 2
Antibody Details
Ki-24
The Ki-24 monoclonal antibody specifically binds to human CD70. CD70 is a type II transmembrane glycoprotein and member of the TNF Superfamily. CD70 is also known as Tumor necrosis factor ligand superfamily member 7 (TNFSF7), CD27 ligand (CD27-L, CD27L, CD27LG), and KI-24 antigen. The CD70 antigen immunoprecipitates as five bands (50, 70, 90, 100 and 160 kDa) under non-reducing conditions. CD70 is strongly expressed on Reed-Sternberg cells, some activated T or B cells and Epstein Barr Virus (EBV)-positive lymphoblastoid cell lines. CD70 plays roles in the activation, proliferation and differentiation of B cells and T cells including the enhanced production of cytotoxic T cells.
The antibody was conjugated to BD Horizon BV786 which is part of the BD Horizon Brilliant™ Violet family of dyes. This dye is a tandem fluorochrome of BD Horizon BV421 with an Ex Max of 405-nm and an acceptor dye with an Em Max at 786-nm. BD Horizon BV786 can be excited by the violet laser and detected in a filter used to detect Cy™7-like dyes (eg, 780/60-nm filter).
565338 Rev. 2
Format Details
BV786
The BD Horizon Brilliant Violet™ 786 (BV786) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an Ex Max of 407-nm and an acceptor dye with an Em Max at 786-nm. BV786, driven by BD innovation, is designed to be excited by the violet laser and detected using a filter, centered near 785 nm (e.g. 780/60 nm bandpass filter). Please ensure that your instrument’s configurations (lasers and filters) are appropriate for this dye.
BV786
407 nm
786 nm
565338 Rev.2
Citations & References
View product citations for antibody "565338" on CiteAb
Development References (9)
-
Bowman MR, Crimmins MA, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S. The cloning of CD70 and its identification as the ligand for CD27. J Immunol. 1994; 152(4):1756-1761. (Biology). View Reference
-
Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:1-1182.
-
Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995.
-
Stein H, Ferszt A, Dallenbach F, et al. CDw70 mAb A109 (Ki-24): expression by reactive and neoplastic lymphoid cells. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:449-451.
-
Stein H, Gerdes J, Lemke H, Mason DY. Evidence of Sternberg-Reed cells being derived from activated lymphocytes. Haematol Blood Transfus. 1985; 29:441-444. (Clone-specific: Immunocytochemistry (cytospins)). View Reference
-
Stein H, Gerdes J, Schwab U, et al. Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells.. Hematol Oncol. 1(1):21-9. (Clone-specific). View Reference
-
Stein H, Gerdes J, Schwarting R, Froese P, Lemke H. Three new lymphoid activation antigens. In: McMichael AJ. A.J. McMichael .. et al., ed. Leucocyte typing III : white cell differentiation antigens. Oxford New York: Oxford University Press; 1987:574.
-
Stein H, Schwarting R, Niedobitek G, Dallenbach F. Activation Section Report. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:387-398.
-
Stein H, Schwarting R, Niedobitek G, Dallenbach F. Cluster report: CDw70. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:446-449.
565338 Rev. 2
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.